Skip to main content
Top
Published in: Digestive Diseases and Sciences 7/2016

01-07-2016 | Rapid Communications

Prevalence of Renal Impairment and Associated Conditions Among HCV-Infected Persons in the Chronic Hepatitis Cohort Study (CHeCS)

Authors: Anne C. Moorman, Xin Tong, Philip R. Spradling, Loralee B. Rupp, Stuart C. Gordon, Mei Lu, Eyasu H. Teshale, Joseph A. Boscarino, Connie M. Trinacty, Mark A. Schmidt, Fujie Xu, Scott D. Holmberg

Published in: Digestive Diseases and Sciences | Issue 7/2016

Login to get access

Abstract

Background

Guidelines for the treatment of HCV-infected persons were updated in August 2015 with new recommendations for patients with renal impairment. Treatment is imperative for patients with severe, renal-associated extrahepatic manifestations of HCV infection.

Aims

We sought to describe the prevalence of these conditions among current HCV-infected patients in a population-based prospective, observational cohort study at four large US health systems.

Methods

Data from cohort patients with chronic HCV infection during 2012 were analyzed for the period from 2006 to 2013. We determined the prevalence of mild to moderately impaired renal function defined as having the most recent estimated glomerular filtration rate [eGFR] ≤ 80 ml/min/1.73 m2, with severe impairment defined as eGFR < 30 ml/min/1.73 m2, based on the treatment guidelines. Prevalence of extrahepatic conditions was ascertained using ICD9-codes.

Results

Among 5772 persons, the prevalence of eGFR ≤ 80 was 33 % and eGFR < 30 was 2 %, including among patients with hepatic fibrosis. Diagnosed extrahepatic renal manifestations were rare: vasculitis- 0.2 %, nephrotic syndrome- 0.3 %, and cryoglobulinemia- 0.9 %.

Conclusions

While the prevalence of severe renal impairment and diagnosed extrahepatic manifestations was low, mild-to-moderate renal impairment was common in HCV patients, including those with advanced liver fibrosis for whom the need for treatment is urgent.
Literature
2.
go back to reference Saxena V, Koraishy F, Sise M, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: real-world experience from HCV-TARGET. 2015 International Liver Congress: 50th Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, April 22–26, 2015. J Hepatol. 2015;62:S267. Saxena V, Koraishy F, Sise M, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: real-world experience from HCV-TARGET. 2015 International Liver Congress: 50th Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, April 22–26, 2015. J Hepatol. 2015;62:S267.
3.
go back to reference Pockros P, Reddy K, Mantry P, et al. Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal-disease: the Ruby-I Study. International Liver Congress: 50th Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, April 22–26, 2015. J Hepatol. 2015;62:S257.CrossRef Pockros P, Reddy K, Mantry P, et al. Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal-disease: the Ruby-I Study. International Liver Congress: 50th Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, April 22–26, 2015. J Hepatol. 2015;62:S257.CrossRef
4.
go back to reference Roth D, Nelson D, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537–1545.CrossRefPubMed Roth D, Nelson D, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537–1545.CrossRefPubMed
5.
go back to reference Terrault N. Difficult-to-cure populations with chronic hepatitis C: vanishing in the direct-acting antiviral era? Hepatology. 2015;62:4–7.CrossRefPubMed Terrault N. Difficult-to-cure populations with chronic hepatitis C: vanishing in the direct-acting antiviral era? Hepatology. 2015;62:4–7.CrossRefPubMed
6.
go back to reference Finelli L, Miller J, Tokars J, et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semi Dial. 2005;18:52–61. Finelli L, Miller J, Tokars J, et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semi Dial. 2005;18:52–61.
8.
go back to reference Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis. 2003;42:631–657.CrossRefPubMed Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis. 2003;42:631–657.CrossRefPubMed
9.
go back to reference Butt AA, Skanderson M, McGinnis KA, et al. Impact of hepatitis C virus infection and other comorbidities on survival in patients on dialysis. J Viral Hepat. 2007;14:688–696.PubMed Butt AA, Skanderson M, McGinnis KA, et al. Impact of hepatitis C virus infection and other comorbidities on survival in patients on dialysis. J Viral Hepat. 2007;14:688–696.PubMed
10.
go back to reference Tsui JI, Vittinghoff E, Shlipak MG, O’Hare AM. Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2006;17:1168–1174.CrossRefPubMed Tsui JI, Vittinghoff E, Shlipak MG, O’Hare AM. Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2006;17:1168–1174.CrossRefPubMed
11.
go back to reference Liangpunsakul S, Chalasani N. Relationship between hepatitis C and microalbuminuria: results from the NHANES III. Kidney Int. 2005;67:285–290.CrossRefPubMed Liangpunsakul S, Chalasani N. Relationship between hepatitis C and microalbuminuria: results from the NHANES III. Kidney Int. 2005;67:285–290.CrossRefPubMed
12.
go back to reference Barsoum RS. Hepatitis C virus: from entry to renal injury-facts and potentials. Nephrol Dial Transplant. 2007;22:1840–1848.CrossRefPubMed Barsoum RS. Hepatitis C virus: from entry to renal injury-facts and potentials. Nephrol Dial Transplant. 2007;22:1840–1848.CrossRefPubMed
14.
go back to reference Allison RD, Tong X, Moorman AC, et al. Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006–2010. J Hepatol. 2015;63:822–828. Allison RD, Tong X, Moorman AC, et al. Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006–2010. J Hepatol. 2015;63:822–828.
15.
go back to reference Gonzaelz HC, Lamerato L, Rogers CG, Gordon SC. Chronic hepatitis C infection as a risk factor for renal cell carcinoma. Dig Dis Sci. 2015;60:1820–1824.CrossRef Gonzaelz HC, Lamerato L, Rogers CG, Gordon SC. Chronic hepatitis C infection as a risk factor for renal cell carcinoma. Dig Dis Sci. 2015;60:1820–1824.CrossRef
16.
go back to reference Perico N, Cattaneo D, Bikbov B, Remuzzi G. Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol. 2009;4:207.CrossRefPubMed Perico N, Cattaneo D, Bikbov B, Remuzzi G. Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol. 2009;4:207.CrossRefPubMed
17.
go back to reference Satapathy S, Lingisetty C, Williams S. Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection. Hepatol Int. 2012;6:369–378.CrossRefPubMed Satapathy S, Lingisetty C, Williams S. Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection. Hepatol Int. 2012;6:369–378.CrossRefPubMed
18.
go back to reference Espinosa M, Martin-Malo A, varez de Lara M, Aljama P. Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. Nephrol Dial Transplant. 2001;16:1669–1674. Espinosa M, Martin-Malo A, varez de Lara M, Aljama P. Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. Nephrol Dial Transplant. 2001;16:1669–1674.
19.
go back to reference Baid-Agrawal S, Pascual M, Moradpour D, Somasundaram R, Muche M. Hepatitis C virus infection and kidney transplantation in 2014: what’s new? Am J Transplant. 2014;14:2206–2220.CrossRefPubMed Baid-Agrawal S, Pascual M, Moradpour D, Somasundaram R, Muche M. Hepatitis C virus infection and kidney transplantation in 2014: what’s new? Am J Transplant. 2014;14:2206–2220.CrossRefPubMed
20.
go back to reference Molnar M, Alhourani H, Wall B, et al. Association of hepatitis C virus infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology. 2015. doi:10.1002/hep.27664. Molnar M, Alhourani H, Wall B, et al. Association of hepatitis C virus infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology. 2015. doi:10.​1002/​hep.​27664.
21.
go back to reference Butt AA, Yan P, Lo Re V, et al. Study Team. Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med. 2015;175:178–185.CrossRefPubMed Butt AA, Yan P, Lo Re V, et al. Study Team. Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med. 2015;175:178–185.CrossRefPubMed
22.
go back to reference Kidney Disease Improving Global Outcomes (KDIGO) Task Force. 2012 Classification of chronic kidney disease. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2013;3:x, 15–18. Kidney Disease Improving Global Outcomes (KDIGO) Task Force. 2012 Classification of chronic kidney disease. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2013;3:x, 15–18.
23.
go back to reference Moorman A, Gordon S, Rupp L, et al. for the CHeCS Investigators. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the Chronic Hepatitis Cohort Study (CHeCS). Clin Infect Dis. 2013;56:40–50. Moorman A, Gordon S, Rupp L, et al. for the CHeCS Investigators. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the Chronic Hepatitis Cohort Study (CHeCS). Clin Infect Dis. 2013;56:40–50.
24.
go back to reference Holmberg S, Lu M, Rupp LB, et al. Use of non-invasive serum markers for staging hepatitis C virus (HCV) in the Chronic Hepatitis Cohort Study (CHeCS). Clin Infect Dis. 2013;57:240–246.CrossRefPubMed Holmberg S, Lu M, Rupp LB, et al. Use of non-invasive serum markers for staging hepatitis C virus (HCV) in the Chronic Hepatitis Cohort Study (CHeCS). Clin Infect Dis. 2013;57:240–246.CrossRefPubMed
25.
go back to reference Li J, Gordon SC, Rupp LB, et al. Lu M; the Chronic Hepatitis Cohort Study (CHeCS) Investigators. The validity of serum markers for fibrosis staging in chronic hepatitis B and C. J Viral Hepat. 2014;21:930–937.CrossRefPubMed Li J, Gordon SC, Rupp LB, et al. Lu M; the Chronic Hepatitis Cohort Study (CHeCS) Investigators. The validity of serum markers for fibrosis staging in chronic hepatitis B and C. J Viral Hepat. 2014;21:930–937.CrossRefPubMed
27.
go back to reference Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate Glomerular filtration rate. Ann Intern Med. 2009;150:604–612.CrossRefPubMedPubMedCentral Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate Glomerular filtration rate. Ann Intern Med. 2009;150:604–612.CrossRefPubMedPubMedCentral
28.
go back to reference Tong X, Spradling P. Increase in nonhepatic diagnoses among persons with hepatitis C hospitalized for any cause, United States, 2004–2011. J Viral Hepat. 2015;22:906–913.CrossRefPubMed Tong X, Spradling P. Increase in nonhepatic diagnoses among persons with hepatitis C hospitalized for any cause, United States, 2004–2011. J Viral Hepat. 2015;22:906–913.CrossRefPubMed
Metadata
Title
Prevalence of Renal Impairment and Associated Conditions Among HCV-Infected Persons in the Chronic Hepatitis Cohort Study (CHeCS)
Authors
Anne C. Moorman
Xin Tong
Philip R. Spradling
Loralee B. Rupp
Stuart C. Gordon
Mei Lu
Eyasu H. Teshale
Joseph A. Boscarino
Connie M. Trinacty
Mark A. Schmidt
Fujie Xu
Scott D. Holmberg
Publication date
01-07-2016
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 7/2016
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-016-4199-x

Other articles of this Issue 7/2016

Digestive Diseases and Sciences 7/2016 Go to the issue

DDS-GRG Profiles and Perspectives

GRG Profiles: Jackie D. Wood

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine